Aytu BioPharma, Inc. (AYTU)
NASDAQ: AYTU · Real-Time Price · USD
2.025
-0.025 (-1.22%)
At close: Oct 9, 2026, 4:00 PM EDT
1.986
-0.039 (-1.91%)
After-hours: Oct 9, 2026, 5:22 PM EDT
Aytu BioPharma Balance Sheet
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash & Equivalents | 26.31 | 30.95 | 20.01 | 22.99 | 19.36 |
Cash & Short-Term Investments | 26.31 | 30.95 | 20.01 | 22.99 | 19.36 |
Cash Growth | -15.00% | 54.71% | -12.96% | 18.72% | -61.01% |
Receivables | 22.78 | 31.16 | 23.53 | 28.73 | 21.71 |
Inventory | 6.86 | 11.43 | 12.14 | 8.51 | 10.85 |
Prepaid Expenses | 5.81 | 5.64 | 5.1 | 5.43 | 7.38 |
Other Current Assets | - | - | 1.12 | 5.43 | 0.63 |
Total Current Assets | 61.76 | 79.18 | 61.89 | 71.08 | 59.93 |
Property, Plant & Equipment | 1.24 | 1.59 | 1.52 | 3.61 | 6.3 |
Other Intangible Assets | 41.4 | 42.2 | 52.45 | 57.44 | 70.63 |
Long-Term Deferred Tax Assets | 0.2 | 0.25 | 0.76 | 1.38 | - |
Other Long-Term Assets | 0.4 | 0.95 | 1.47 | 2.96 | 0.77 |
Total Assets | 105.01 | 124.18 | 118.1 | 136.46 | 137.62 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Accounts Payable | 11.28 | 10.6 | 10.31 | 12.55 | 10.99 |
Accrued Expenses | 14.18 | 15.26 | 22.26 | 24.54 | 25.71 |
Short-Term Debt | 6.07 | 9.06 | 2.4 | 1.56 | 3.81 |
Current Portion of Long-Term Debt | 1.86 | 1.86 | 1.86 | - | - |
Current Portion of Leases | 0.22 | 0.14 | 0.71 | 1.34 | 0.1 |
Other Current Liabilities | 21.04 | 26.15 | 24.69 | 29.02 | 23.84 |
Total Current Liabilities | 54.66 | 63.06 | 62.23 | 69.02 | 64.44 |
Long-Term Debt | 9.1 | 10.9 | 10.88 | 14.71 | 14.2 |
Long-Term Leases | 0.85 | 0.99 | 0.58 | 0.83 | 0.08 |
Long-Term Deferred Tax Liabilities | 0.2 | 0.25 | 0.76 | 1.38 | - |
Other Long-Term Liabilities | 4.92 | 30.02 | 15.94 | 11.17 | 14.59 |
Total Liabilities | 69.73 | 105.21 | 90.38 | 97.11 | 93.32 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Common Stock | 0 | 0 | 0 | 0 | - |
Additional Paid-In Capital | 383.06 | 352.5 | 347.69 | 343.49 | 331.39 |
Retained Earnings | -347.79 | -333.54 | -319.97 | -304.13 | -287.08 |
Total Common Equity | 35.27 | 18.97 | 27.72 | 39.36 | 44.31 |
Shareholders' Equity | 35.27 | 18.97 | 27.72 | 39.36 | 44.31 |
Total Liabilities & Equity | 105.01 | 124.18 | 118.1 | 136.46 | 137.62 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Total Debt | 18.11 | 22.94 | 16.42 | 18.45 | 18.19 |
Net Cash (Debt) | 8.2 | 8.02 | 3.59 | 4.53 | 1.17 |
Net Cash Growth | 2.33% | 123.38% | -20.87% | 286.86% | -95.29% |
Net Cash Per Share | 0.67 | 1.28 | 0.65 | 1.36 | 0.80 |
Filing Date Shares Outstanding | 10.87 | 9.91 | 6.17 | 5.53 | 3.12 |
Total Common Shares Outstanding | 10.73 | 8.98 | 5.97 | 5.52 | 1.93 |
Working Capital | 7.1 | 16.12 | -0.34 | 2.06 | -4.51 |
Book Value Per Share | 3.29 | 2.11 | 4.64 | 7.13 | 22.97 |
Tangible Book Value | -6.13 | -23.24 | -24.74 | -18.08 | -26.32 |
Tangible Book Value Per Share | -0.57 | -2.59 | -4.14 | -3.28 | -13.65 |
Machinery | 1.03 | 1.08 | 2.78 | 4.29 | 4.45 |
Construction In Progress | - | - | - | 0.11 | - |
Leasehold Improvements | 0.16 | 0.16 | 0.04 | 1 | 1 |